First-in-Human Phase I Trial of HRS-2129, a Selective Nav1.8 Inhibitor: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
Abstract
Background: HRS-2129 is a novel, orally administered, selective Nav1.8 sodium channel blocker under development for pain management. This first-in-human study evaluated its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy subjects.
Methods: Two randomized, double-blind, placebo-controlled studies were conducted: a single ascending dose (SAD) study (25-600 mg, n=44) and a multiple ascending dose (MAD) study (25 mg BID, 25 mg QD, 75 mg QD, n=23). Safety, PK, and PD (cold/heat pain thresholds and pain tolerance time) were assessed.
Results: HRS-2129 exhibited favorable tolerability following a single administration (25-600 mg) and repeated dosing at 25 mg BID. No severe or serious adverse events (SAEs) occurred in the SAD study. One SAE (drug rash) led to discontinuation in the 75 mg QD cohort during the MAD phase. Common AEs were mild and included proteinuria, occult blood, and ECG T-wave abnormalities. PK analysis showed rapid absorption, a long half-life supporting once-daily dosing, less than dose-proportional exposure, and moderate accumulation at steady state. Food delayed absorption without affecting overall exposure. PD results showed increased pain tolerance time in the ice-water bath test without clear dose dependency.
Conclusion: Within the evaluated dose range, HRS-2129 demonstrated a favorable safety profile, predictable PK with low accumulation, and preliminary evidence of analgesic effect. These results support further clinical…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 44 participants or records.
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.